Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Rajashekhar Betageri

John Robert Proudfoot

David S Thomson

Daniel Kuzmich

Usha R Patel

Montse Llinas-Brunet

Neil Moss

Renee M Zindell

Jean-Marie Ferland

Pierre Louis Beaulieu

Hossein Razavi

Mario G Cardozo

Pingrong Liu

Doris Riether

Yan Zhang

John Lord

Darren DiSalvo

Christian Harcken

Eugene R Hickey

John R Regan

Karl D Hargrave

Hidenori Takahashi

Todd Bosanac

Soojin Kim

Sanxing Sun

Lifen Wu

Thomas Martin Kirrane, Jr

Abdelhakim Hammach

Charles Lawrence Cywin

Angela Kay Berry

Michael Jason Burke

Xiao-Jun Wang

Michel Jose Emmanuel

Younes Bekkali

Thomas A Gilmore

Can Mao

Brian Nicholas Cook

Jonathan Timothy Reeves

Ji Wang

Jennifer A Kowalski

Rajiv Sharma

Someina Khor

Christian Hanke Justus Joachim Harcken

Thomas Wai-ho Lee

Thomas M Kirrane

Thomas Wai-Ho Lee

Eugene Richard Hickey

Mary Ann Hoermann

Thomas M Parks

Zhibin Li

Boehringer Ingelheim Pharma GMBH&CO Kg Kg

Compounds of Formula (IA), (IB), (IC), and (ID) wherein R, R, R, R, R, and Rare as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain (I). 

Pyrrolidine compounds which modulate the CB2 receptor

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.  Also disclosed are methods of making and methods of using same.

Pyrazolopiperidine compounds as CCR1 receptor antagonists

Compounds of Formula (I) wherein R, R, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Compounds of Formula (IA) wherein R, R, R, Rand Rare as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Compounds of Formula (I) wherein R, R, R, R, R, R, and Rare as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

A compound of Formula (I) wherein R, R, R, R, R, and Rare as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof

A compound of Formula (I)wherein R, R, R, R, R, and Rare as defined herein, or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents

1-(4-aminophenyl)pyrazoles optionally substituted on the 3- and 5-positions of the pyrazole ring and on the amino group at the 4-position of the phenyl ring are disclosed and described, which pyrazoles inhibit IL-2 production in T-lymphocytes.

Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents

This invention relates to compounds of formula (I):

Src family SH2 domain inhibitors

This invention relates to compounds of formula (1):

Disclosed are compositions containing compounds of the formula (I) below wherein A,B,C,G,Q and R are defined herein. The compounds are useful as phosphotyrosine mimics that, when incorporated into an appropriate molecular structure, inhibit the binding of tyrosine kinase-dependent regulatory proteins to their native phosphotyrosine-containing ligands or receptors. Also disclosed are methods for preparing the compounds of the formula (I). ##STR1##

Compounds useful as phosphotyrosine mimics

This invention relates to compounds of formula (1): ##STR1## wherein Ring a, A, B, C, D, E, R and Q are defined herein. These compounds possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands.

Growing community of inventors

Bethel, CT, United States of America

Rajashekhar Betageri